Cover Image
Market Research Report

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2016 in Pharmaceuticals

Published by GlobalData Product code 248823
Published Content info 97 Pages
Immediate Delivery Available
Price
Back to Top
Partnerships, Licensing, Investments and M&A Deals and Trends for July 2016 in Pharmaceuticals
Published: September 1, 2016 Content info: 97 Pages
Description

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for July 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Table of Contents
Product Code: GDPH0500MD

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 8

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12

  • 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, July 2016 12
  • 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, July 2016 14
    • 2.2.1 Teva Pharma Raises USD15 Billion in Public Offering of Notes 14
    • 2.2.2 Teva Pharma Raises USD4.4 Billion in Additional Public Offering of Notes 15
    • 2.2.3 Celgene Enters into Agreement with Jounce Therapeutics 15
    • 2.2.4 Galenica to Acquire Relypsa for USD1.53 Billion in Tender Offer 16
    • 2.2.5 AstraZeneca to Enter into Co-Marketing Agreement with Aspen 17
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, July 2016 19
  • 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, July 2016 20

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 21

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, July 2016 21
    • 3.1.1 Top M&A Deals in July 2016 22
    • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, February 2016 - July 2016 23
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, July 2016 24
    • 3.2.1 Top Equity Offering Deals in July 2016 25
    • 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, February 2016 - July 2016 26
  • 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, July 2016 27
    • 3.3.1 Top PE/VC Deals in July 2016 28
    • 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, July 2016 29
    • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, July 2016 30
    • 3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, February 2016-July 2016 31
    • 3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, February 2016-July 2016 32
  • 3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, July 2016 33
  • 3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, February 2016 - July 2016 35
  • 3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), July 2016 36
    • 3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, July 2016 37
  • 3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), February 2016 - July 2016 38
  • 3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, February 2016 - July 2016 40
  • 3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), February 2016 - July 2016 41
  • 3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), February 2016 - July 2016 42

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, July 2016 43

  • 4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, July 2016 43
  • 4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), July 2016 45
  • 4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), February 2016 - July 2016 47
  • 4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), February 2016 - July 2016 49
  • 4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), February 2016 - July 2016 51
  • 4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), February 2016 - July 2016 53
    • 4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, July 2016 54
    • 4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, July 2016 55
    • 4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, July 2016 55

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 56

  • 5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, July 2016 56
    • 5.1.1 Oncology - Deals of the Month 57
  • 5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, July 2016 59
    • 5.2.1 Central Nervous System - Deals of the Month 60
  • 5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, July 2016 61
    • 5.3.1 Infectious Diseases - Deals of the Month 62
  • 5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, July 2016 64
    • 5.4.1 Cardiovascular - Deals of the Month 65
  • 5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, July 2016 67
    • 5.5.1 Immunology - Deals of the Month 68
  • 5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, July 2016 71
    • 5.6.1 Gastrointestinal - Deal of the Month 72
  • 5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, July 2016 75
    • 5.7.1 Metabolic Disorders - Deal of the Month 76

6 Deal Summary by Geography 77

  • 6.1 Pharmaceuticals & Healthcare, North America Deals, July 2016 77
    • 6.1.1 North America - Deals of the Month 78
  • 6.2 Pharmaceuticals & Healthcare, Europe, Deals, July 2016 81
    • 6.2.1 Europe - Deals of the Month 82
  • 6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, July 2016 84
    • 6.3.1 Asia-Pacific - Deals of the Month 85
  • 6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, July 2016 87
    • 6.4.1 Rest of the World - Deals of the Month 88

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 90

  • 7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, February 2016 - July 2016 90
  • 7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, February 2016 - July 2016 92

8 Further Information 94

  • 8.1 Methodology 94
  • 8.2 About GlobalData 95
  • 8.3 Disclosure information 95
  • 8.4 Disclaimer 96

List of Tables

1.1 List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 13
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, July 2016 14
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), July 2016 20
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 22
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, July 2016 22
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, February 2016 - July 2016 23
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 25
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, July 2016 25
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 26
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 28
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, July 2016 28
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, February 2016 - July 2016 29
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), July 2016 31
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 32
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, February 2016 - July 2016 32
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 34
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 35
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2016 - July 2016 36
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), July 2016 37
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), February 2016 - July 2016 39
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, February 2016 - July 2016 41
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), February 2016 - July 2016 42
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 44
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), February 2016 - July 2016 46
  • Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 48
  • Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), July 2016 50
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, February 2016 - July 2016 52
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), July 2016 54
  • Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, July 2016 54
  • Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, July 2016 55
  • Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, July 2016 55
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 57
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 60
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 62
  • Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 65
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 68
  • Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 72
  • Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 76
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 78
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 82
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 85
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 88
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 91
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 93

List of Figures

1.2 List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 12
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), July 2016 19
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), July 2016 20
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 21
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, February 2016 - July 2016 23
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 24
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 26
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 27
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, February 2016 - July 2016 29
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), July 2016 30
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), July 2016 30
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 31
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 33
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 35
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2016 - July 2016 36
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), February 2016 - July 2016 38
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, February 2016 - July 2016 40
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, February 2016 - July 2016 41
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), February 2016 - July 2016 42
  • Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 43
  • Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2016 - July 2016 45
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 47
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), February 2016 - July 2016 49
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, February 2016 - July 2016 51
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), February 2016 - July 2016 51
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), July 2016 53
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 56
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 59
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 61
  • Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 64
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 67
  • Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 71
  • Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 75
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 77
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 81
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 84
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 87
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 90
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), February 2016 - July 2016 92
Back to Top